Study Drugs and method of infusion | Pharmacokinetic Sampling | Pharmacodynamic Targets tested |
---|---|---|
Beta-lactam antibiotics by intermittent infusion | Sample A: mid-way through dosing interval (50% of dosing interval) | · 50% f T>MIC |
(amoxycillin-clavulanate; ampicillin; piperacillin-tazobactam; penicillin-G; flucloxacillin; dicloxacillin; cloxacillin; cephazolin; ceftazidime; ceftriaxone; cefepime; meropenem; imipenem; doripenem; ertapenem) | Sample B: within 30 min of next dose (100% of dosing interval) | · 50% f T>4xMIC* |
Glycopeptide antibiotics by intermittent infusion (vancomycin, teicoplanin) | · 100% f T>MIC | |
· 100% f T>4xMIC | ||
· 100% f T>4xMIC | ||
· Concentration ≥15 mg/L* | ||
Triazole antifungals (fluconazole, voriconazole) | Sample A: 30 min after completion of intravenous infusion (peak concentration) | · AUC0-24/MIC ≥25* |
Echinocandin antifungals (caspofungin, micafungin, anidulafungin) | Sample B: mid-way through dosing interval (50% of dosing interval) | · AUC0-24/MIC ≥20* |
Sample C: within 30 min of next dose (100% of dosing interval) | ||
Beta-lactam antibiotics (listed above) by continuous infusion | Sample A: at any time | · 100% f T>4xMIC* |
Sample B: >6 hours after sample A | ||
Glycopeptide antibiotics (listed above) by continuous infusion | · 100% f T>4xMIC* | |
· AUC0-24/MIC ≥350 |